Cardiovascular effects of ATG and OKT3 in renal allograft recipients.
Spieker
C
C
Medizinische Poliklinik, Westfälischen Wilhems-Universität, Münster, Germany.
Barenbrock
M
M
Buchholz
B
B
Heidenreich
S
S
Zidek
W
W
D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects*; D002102:Cadaver; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy*; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000009:adverse effects*; D011183:Postoperative Complications / Q000276:immunology / Q000628:therapy*
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3